Global Single-cell Omics Market Size, Forecast, and Trend Highlights Over 2025-2037
Single-cell Omics Market size was over USD 4.44 billion in 2024 and is likely to reach USD 59.52 billion by the end of 2037, witnessing around 22.1% CAGR during the forecast period i.e., between 2025-2037. In 2025, the industry size of single-cell omics is estimated at USD 5.22 billion.
A demographic-based prediction from the American Cancer Society calculated the new and death cases of malignancy worldwide to be 20 million in 2022, which is further estimated to reach 35 million by 2050. It also mentioned the count of mortality resulted by this ailment to be and 9.7 million in 2022. Single-cell omics provide a powerful tool to segregate and analyze carcinoma cells individually, helping researchers identify the targets that contribute to tumor development progression and response to therapy. This signifies the importance of this transcription method in extensive clinical research. Thus, the continuous demand for personalized medicine in this category is fueling growth in the single-cell omics market.
On this note, a 2021 NLM study revealed that the advances in functional single-cell omics improved the understanding of intra-patient diversity and biological mechanisms of tumour evolution, prognosis, and drug resistance in cancer. However, the enlarging financial exhaustion on cancer patients has become a serious issue, where ongoing R&D cohorts aim at reducing this burden. According to an article published by the ASCO Publication, the annual spending per patient on related treatments, such as CAR T-cell therapy, was USD 500,000.0 till 2021. Thus, the efforts from both public and private organizations are currently dedicated to decrease the payers’ pricing of these therapeutics to make it more accessible by lowering the cost of analysis per cell for research-associated individuals.
Single-cell Omics Sector: Growth Drivers and Challenges
Growth Drivers
- Extending field of applications: Advancements and wide commercialization of sequencing is broadening the utilization territory of the single-cell omics market. As this technique provides a comprehensive snapshot of gene expression profiles in cells, researchers are increasingly investing in this sector to identify and characterize distinct cell populations and subtypes within a tissue or organism. This garnering higher avenues for development and opportunities of business from various medical disciplines beyond oncology for this sector. This new line of applications includes: optimization of cell lines for biologics production, neuroscience, infectious disease, stem cell research, and clinical diagnostics.
- Tech-based integration in analysis: The single-cell omics market is rapidly evolving, driven by continuous advancements in technologies and methodologies. The enhanced workflow and seamless operation attract giant research institutions and fuel the demand for these innovative products. For instance, in June 2024, Mission Bio introduced Tapestri Single-cell Multiple Myeloma Multiomics Solution to accelerate the multiple myeloma (MM) research and therapeutic development. It is designed to offer comprehensive clonal and subclonal insights into disease evolution and biology at the single-cell level, featuring automated data analysis & reporting and compatibility with the existing Tapestri Instruments.
Challenges
- Complexity and expensiveness of this technique: Affordability and cost-effectiveness of the commodities from the single-cell omics market are significant considerations for their widespread implementation, especially in resource-limited settings or for small research institutes. Despite the efforts to provide financial support from government and manufacturing companies, the need for specialized equipment, reagents, and data analysis resources adds to the overall cost. In addition, the complicated procedure and pressure of regulatory compliance often creates a hurdle for worldwide adoption.
Single-cell Omics Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
22.1% |
|
Base Year Market Size (2024) |
USD 4.44 billion |
|
Forecast Year Market Size (2037) |
USD 59.52 billion |
|
Regional Scope |
|
Single-cell Omics Segmentation
Application (Immunology, Neurology, Oncology, Cell Biology)
By 2037, the oncology sector is estimated to captivate the largest share of 46% in the global single-cell omics market. The growth of the segment can be attributed to the rise in the number of gene therapy trials focusing on genomics in cancer care. According to the American Society of Gene & Cell Therapy, 97.0% of the under-development CAR-T cell therapies belonged to oncology till 2024. Even in the gene therapy pipeline (preclinical to pre-registration), this category captured the highest proportion of 54.0%, accounting for 1123 developments. Furthermore, the rapid expansion of the precision oncology industry, which is poised to reach USD 124.8 billion by 2025 and USD 411.9 billion by 2037, is also an indication of this segment’s proprietorship.
End user (Pharmaceutical & Biotechnology Companies, Research Organization, Hospitals)
The research organization segment is projected to hold 55% share of the global single-cell omics market over the assessed timeline. Rising investment from both public and private organizations to accelerate the development progress in the research facilities is empowering the segment’s revenue generation. For instance, in March 2023, Schmidt Futures allocated a USD 50.0 million fund to the latest research facility aimed at creating single-cell proteomics technologies for various clinical disciplines, such as Alzheimer’s disease. Such financial support empowers procurement of advanced equipment, such as high-throughput sequencers, single-cell isolation systems, and imaging platforms, ensuring a stable capital influx in this segment.
Our in-depth analysis of the global single-cell omics market includes the following segments:
|
Application |
|
|
Product |
|
|
End user |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportSingle-cell Omics Industry - Regional Synopsis
North American Market Forecast 
The North America single-cell omics market is projected to be the largest with a share of about 40% throughout the analyzed timeframe. The growth of this landscape is credited to the rising investment in advanced healthcare technologies, backed by the strong presence of global MedTech pioneers. In this regard, in July 2024, Illumina acquired Fluent BioSciences to accelerate single-cell analysis and discovery to a broader customer base. The growing popularity and commercial participation in genomics, molecular diagnostics, and bioinformatics are also contributing to the region’s leadership. This can also be testified by its dominance over the global precision medicine industry, presenting a potential to capture 45.0% share by 2037.
The U.S. is augmenting the single-cell omics market with an enlarging biotechnology industry and a strong emphasis on biopharmaceutical R&D. As per the Pharmaceutical Research and Manufacturers Association, the biotech industry in this country secured 13.0% of the total venture capital investments in 2023. It also mentioned that the R&D expenditure by U.S.-based biopharmaceutical companies totaled up to USD 96.0 billion in the same year. Similarly, in 2022, the foreign-owned biopharma firms spent USD 26.0 billion in this category. This scenario reflects the rigorous activity and continuous capital influx in this sector.
APAC Market Statistics
The Asia Pacific single-cell omics market is expected to be the second largest, with a share of over 27% and a remarkable CAGR of 18% over the discussed period. The rise in the collaboration of companies is poised to bring new business opportunities for this landscape. For instance, in December 2021, Mission Bio partnered with SequMed to provide Tapestri Services and co-develop novel single-cell assays in China. This partnership was aimed at combining the capabilities of products from both the companies to expand their applications to cope with the nationwide surge for innovations in reproductive genetics and clinical diagnosis. Such events showcase the growing interest of local and foreign investors in this merchandise.
India is emerging as one of largest hub of biopharmaceutical innovators and manufacturers in the single-cell omics market. Several factors, such as the emphasizing MedTech industry, foreign investments, and large patient pool, are accumulatively contributing to this nation’s progress in this field. On this note, IBEF estimated the biotechnology industry in India to generate a value of USD 300.0 billion by 2030. It also mentioned that the country is the biggest supplier of affordable vaccines, accounting for 50.0% of the global demand. These figures highlight the significance of India as a lucrative opportunity of investment and profitable trading for global pioneers.
Companies Dominating the Single-cell Omics Landscape
- Ultima Genomics, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- 10x Genomics, Inc.
- Becton, Dickinson and Company (BD)
- CELLENION
- PerkinElmer Inc.
- ANGLE plc
- Illumina, Inc.
- Bio-Rad Laboratories, Inc.
- Mission Bio, Inc.
- Standard BioTools Inc.
- Scale Biosciences, Inc.
- Takara Bio USA Holdings, Inc.
Key players in the single-cell omics market are changing their dynamics by incorporating advanced technologies such as multi omics, AI-powered analysis, and spatial sequencing. Their focus is concentrated on improving the performance and utility of their products by leveraging their capabilities. In this regard, in March 2024, BioSkryb Genomics commercialized its new ResolveDNA Whole Genome, ResolveOME Whole Genome, and Transcriptome Single-Cell Core Kits in the U.S. and international market, offering fast and seamless workflow. Similarly, in October 2024, 10x Genomics two new Chromium products, GEM-X Flex and GEM-X Universal Multiplex, to upscale the performance, workflow, and cost effectiveness for researchers associated with single-cell analysis. Such key players are:
In the News
- In April 2025, Scale Bio participated in the Chan Zuckerberg Initiative's Billion Cells Project at the Chan Zuckerberg Biohub, New York Affiliate Symposium. The company joined forces of global Biotech firms to fuel rapid progress in single-cell biology through AI model development.
- In February 2025, Illumina launched a series of innovations to expand its portfolio of omics solutions and sequencing applications. The pipeline includes: spanning genomics, spatial transcriptomics, single cell analysis, CRISPR technologies, epigenetics, and data analytics software.
- In January 2025, Takara Bio USA Holdings acquired Curio Bioscience to leverage its portfolio of single-cell genomics tools with the integration of two innovative spatial biology platforms. This acquisition allowed the company to possess Curio’s Trekker and Seeker technologies to offer high-resolution insights.
Author Credits: Radhika Pawar
- Report ID: 5060
- Published Date: May 02, 2025
- Report Format: PDF, PPT
